News

Doheny Eye Institute announced Ghosh was recognized by Research to Prevent Blindness and the International Retinal Research Foundation.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Alice Epitropoulos, MD, goes over meibomian gland dysfunction and the most common reasons it is missed in diagnosis and how to avoid them.

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.

The event is a forum for the exchange of ideas between leading scientists in diverse fields to bring their knowledge to the challenges of glaucoma and help set the course for future glaucoma research.

Surgeons from iLink Centers of Excellence offer pearls, from optimal scheduling to networking.

The country is home to 20% of biotechs headquartered in Europe.

The European Society of Ophthalmology (SOE) 2023 Congress will convene from June 15 to 17 in Prague, Czech Republic.

SOE holds a special place in its heart for the up-and-coming young ophthalmologists and is providing them a number of opportunities to hone their skills and establish professional contacts at this meeting.

The organization aims to educate patients and doctors on one of the leading causes of blindness worldwide.

Prevent Blindness marks its 115th birthday on June 1 by declaring it Prevent Blindness Day.

According to the company, topline results from the clinical trial are expected by the third quarter of 2024.

Reaching target enrollment is an important step toward Nacuity's goal to realize the potential of NPI-001 for patients affected by retinitis pigmentosa.

According to the company, the Phase 1/2 SLO-RP trial completed target enrollment of 48 patients diagnosed with RP associated with USH, with interim efficacy data anticipated by the end of the year.

Treatment option offers positive outcome for patients diagnosed with disease.

Ground-breaking treatment for bullous keratopathy approved in Japan

This positive data supports Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.

Optos announced the first ultra-widefield color rgb (red/green/blue) image. This new image modality is captured simultaneous to the optomap color rg image.

According to the company, CTx-PDE6b in patients with retinitis pigmentosa caused by bi-allelic mutations in PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile.

World No Tobacco Day helps to bring focus onto risk factors and symptoms of early vision loss linked to smoking.

The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities, such as transgender women or nonbinary donors, will be impacted.

Therapeutic has fewer adverse effects in patients with POAG, OHT.

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show